Consent Judgment Acknowledges the Validity and Enforceability of Cytomedix's Knighton Patent

Separate Judgment Also Entered in Louisiana Trade Secrets Action in Favor of Cytomedix and Its Distributor


LITTLE ROCK, Ark., June 21, 2004 (PRIMEZONE) -- Cytomedix, Inc. (OTCBB:CYME) today announced that on June 8, 2004, the United States District Court for the Northern District of Illinois entered a consent judgment against 21st Century Wound Care and Advanced Therapy, L.L.C., and its owner, James Gandy. In that consent judgment, 21st Century Wound Care and Mr. Gandy admitted that Cytomedix's Knighton patent, which covers the use of compositions containing platelet releasates for wound healing purposes, is valid and enforceable. The Court declared that 21st Century Wound Care and Gandy had infringed the Knighton Patent and enjoined them, effective immediately and continuing through expiration of the Knighton patent in November 2009, from making, using, offering, or selling within the United States autologous cellular therapies, platelet gel products, or any other processes or products-such as their "P-Gel" formulation-that infringe the claims of the Knighton Patent. The Court's injunction is binding on 21st Century Wound Care and Mr. Gandy, and on those acting in concert or participation with them. The Court retained jurisdiction to enforce its order of judgment.

Separately, the United States District Court for the Eastern District of Louisiana entered a judgment, also on June 8, 2004, in favor of Cytomedix and CPP Wound Care LLC, d/b/a Louisiana Wound Care Specialists-Cytomedix's leading distributor of AutoloGel(tm) in Louisiana. In that action, filed in April 2004, 21st Century Wound Care and Gandy alleged that Cytomedix and CPP Wound Care/Louisiana Wound Care Specialists had misappropriated from them certain trade secrets underlying the AutoloGel(tm) System. The Court entered the judgment against 21st Century Wound Care and Mr. Gandy "with prejudice."

"This legal matter underscores Cytomedix's commitment to aggressively pursuing any infringement of the company's intellectual property. We are pleased to have successfully resolved this matter and look forward to other positive developments related to our AutoloGel(tm) System," said Dr. Kshitij Mohan, chief executive officer of Cytomedix.

About Cytomedix

Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates. The current product offering is AutoloGel(tm), an autologous platelet gel composed of multiple growth factors and fibrin matrix, which is used to treat chronic wounds. Cytomedix is working with healthcare providers to offer an advanced therapy at the point-of-care in multiple settings. Additional information is available at: www.cytomedix.com.

Forward Looking Statements

Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, governmental regulation, acceptance by the medical community and competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.



            

Contact Data